Globavend vs Cellyan Biotechnology
GVH and HKPD side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GVH and HKPD compare
Globavend grew revenue faster over the last twelve months (42.5% versus −33.9% for Cellyan Biotechnology).
Globavend keeps more of each dollar of sales as profit, with a net margin of 2.9% compared with −8.5% at Cellyan Biotechnology.
Globavend scores higher on the StockData Score (9 against 3 for Cellyan Biotechnology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GVH | HKPD |
|---|---|---|
| Size and price | ||
| Share price | $0.772 | $1.52 |
| Change, 1 year | −80.4% | −93.5% |
| Beta (5Y) | 2.71 | – |
| Employees | 9 | 2 |
| StockData Score | ||
| Total score | 9 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 3 (better) | 1 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 42.5% (better) | −33.9% |
| Net income growth (TTM) | −49.0% | – |
| EPS growth (TTM) | −91.2% | – |
| Profitability | ||
| Gross margin | 10.1% | 10.3% (better) |
| Operating margin | 4.1% (better) | −17.8% |
| Net margin | 2.9% (better) | −8.5% |
| FCF margin | 0.98% (better) | −5.9% |
| Return on equity | 8.5% (better) | −15.5% |
| Return on invested capital | 18.6% (better) | −22.5% |
| Financial health | ||
| Debt / equity | 0.00 | 0.09 (better) |
| Interest coverage | 963× (better) | −17.8× |
| Current ratio | 9.95 (better) | 3.86 |
| Piotroski F-score | 4 (better) | 3 |
| Ownership | ||
| Held by institutions | 1.3% | 1.5% |
| Held by insiders | 7.8% | 81.9% |
| Insider net buying, 12 months | $4.2K | – |
| Short interest, % of float | 1.4% | 0.57% |
Go deeper
- GVH stock overview
- GVH income statement
- GVH valuation and score
- HKPD stock overview
- HKPD income statement
- HKPD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.